Clinical Trial Update: Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2A/B study evaluating the efficacy and safety of dabogratinib in participants with Low Grade Upper Tract Urothelial Carcinoma is currently recruiting. Spo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Upper Tract Urothelial Carcinoma

Drugs mentioned

• Dabogratinib (dabogratinib)

Snippet

Sponsor: Tyra Biosciences, Inc | Conditions: Low Grade Upper Tract Urothelial Carcinoma | Phase 2 | Status: RECRUITING